Evidence map›Paper›PMID 31281652›Full record

ArticleMolecular and clinical oncology2019

Pneumothorax following combination chemotherapy with bevacizumab: A case report and review of the literature.

Taha Alrifai, Raya Saba, Dana Rifai, Sarbagya Pandit, Kelley E Kozma

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular and clinical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Taha AlrifaiDepartment of Internal Medicine, Saint Joseph Hospital, Chicago, IL 60657, USA.
Raya SabaDepartment of Hospital Medicine, John T. Milliken Department of Medicine, Washington University, St. Louis, MO 63110, USA.
Dana RifaiDepartment of Internal Medicine, St. Catherine Hospital, East Chicago, IN 46312, USA.
Sarbagya PanditDepartment of Internal Medicine, Saint Joseph Hospital, Chicago, IL 60657, USA.
Kelley E KozmaDepartment of Hematology and Oncology, Saint Joseph Hospital, Chicago, IL 60657, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bevacizumab (BV) is a humanized monoclonal antibody that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF). The addition of BV to combination chemotherapy has been shown to improve the outcomes in several malignancies, including colorectal carcinoma (CRC). However, the use of BV has been associated with adverse effects, including hypertension, hemorrhage, proteinuria, delayed wound healing and bowel perforation. Pneumothorax (PTX) as an adverse event associated with BV use has rarely been reported. We herein report the case of a 68-year-old female patient with a history of metastatic CRC treated with combination chemotherapy, including BV, who presented with complaints of shortness of breath and was found to have a right-sided PTX.

Indexed as

adverse reactionsbevacizumaboncologypneumothoraxvascular endothelial growth factor inhibitors

Identifiers

PMID31281652
PMCPMC6587012

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.